Y. A. Abassi, B. Xi, W. Zhang, P. Ye, S. L. Kirstein et al., Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects, Chem. Biol, vol.16, pp.712-723, 2009.

J. P. Adler-moore and R. T. Proffitt, Amphotericin B lipid preparations: what are the differences?, Clin. Microbiol. Infect, vol.14, pp.25-36, 2008.

A. Anadon, M. A. Martinez, V. Castellano, and M. R. Martinez-larranaga, The role of in vitro methods as alternatives to animals in toxicity testing, Expert Opin. Drug Metab. Toxicol, vol.10, pp.67-79, 2014.

A. P. Bellanger, L. Millon, K. Khoufache, D. Rivollet, I. Bieche et al., Aspergillus fumigatus germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549, J. Med. Microbiol, vol.58, pp.174-179, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00448417

O. A. Cornely, J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann et al., Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N. Engl. J. Med, vol.356, pp.348-359, 2007.

R. H. Drew, E. Dodds-ashley, D. K. Benjamin, D. Davis, R. Palmer et al., Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients, Transplantation, vol.77, pp.232-237, 2004.

D. R. Falci, F. B. Da-rosa, and A. C. Pasqualotto, Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study, Mycoses, vol.58, pp.104-112, 2015.

M. Fauvel, C. Farrugia, N. Tsapis, C. Gueutin, O. Cabaret et al., Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity, Int. J. Pharm, vol.436, pp.106-110, 2012.

J. Gavalda, M. T. Martin, P. Lopez, X. Gomis, J. L. Ramirez et al., Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis, Antimicrob. Agents Chemother, vol.49, pp.3028-3030, 2005.

D. E. Geller, M. W. Konstan, J. Smith, S. B. Noonberg, and C. Conrad, Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety, Pediatr. Pulmonol, vol.42, pp.307-313, 2007.

F. Guo, N. Ma, Y. Horibe, S. Kawanishi, M. Murata et al., Nitrative DNA damage induced by multi-walled carbon nanotube via endocytosis in human lung epithelial cells, Toxicol. Appl. Pharmacol, vol.260, pp.183-192, 2012.

N. Jessberger, R. Dietrich, S. Bock, A. Didier, and E. Martlbauer, Bacillus cereus enterotoxins act as major virulence factors and exhibit distinct cytotoxicity to different human cell lines, Toxicon, vol.77, pp.49-57, 2014.

N. Ke, X. Wang, X. Xu, and Y. A. Abassi, The xCELLigence system for real-time and label-free monitoring of cell viability, Methods Mol. Biol, vol.740, pp.33-43, 2011.

M. Larabi, P. Legrand, M. Appel, S. Gil, M. Lepoivre et al., Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers, Antimicrob. Agents Chemother, vol.45, pp.553-562, 2001.

M. Larabi, V. Yardley, P. M. Loiseau, M. Appel, P. Legrand et al., Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B, Antimicrob. Agents Chemother, vol.47, pp.3774-3779, 2003.

M. Larabi, N. Pages, F. Pons, M. Appel, A. Gulik et al., Study of the toxicity of a new lipid complex formulation of amphotericin B, J. Antimicrob. Chemother, vol.53, pp.81-88, 2004.

P. Legrand, M. Cheron, L. Leroy, and J. Bolard, Release of amphotericin B from delivery systems and its action against fungal and mammalian cells, J. Drug Target, vol.4, pp.311-319, 1997.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, vol.25, pp.402-408, 2001.

O. Lortholary, J. P. Gangneux, K. Sitbon, B. Lebeau, F. De-monbrison et al., Epidemiological trends in invasive aspergillosis in France: the SAIF network, Clin. Microbiol. Infect, vol.17, pp.1882-1889, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00680990

J. Menotti, Toxicology and Applied Pharmacology, vol.334, pp.18-23, 2017.

C. M. Lowry, F. M. Marty, S. O. Vargas, J. T. Lee, K. Fiumara et al., Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study, Transpl. Infect. Dis, vol.9, pp.121-125, 2007.

V. Monforte, A. Lopez-sanchez, F. Zurbano, P. Ussetti, A. Sole et al., Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant, J Heart Lung Transplant, vol.32, pp.313-319, 2013.

J. Obaji, L. R. Lee-pack, C. Gutierrez, and C. K. Chan, The pulmonary effects of longterm exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients, Chest, vol.123, pp.1983-1987, 2003.

J. A. Olson, J. P. Adler-moore, G. M. Jensen, J. Schwartz, M. C. Dignani et al., Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products, Antimicrob. Agents Chemother, vol.52, pp.259-268, 2008.

S. M. Palmer, R. H. Drew, J. D. Whitehouse, V. F. Tapson, R. D. Davis et al., Safety of aerosolized amphotericin B lipid complex in lung transplant recipients, Transplantation, vol.72, pp.545-548, 2001.

B. J. Rijnders, J. J. Cornelissen, L. Slobbe, M. J. Becker, J. K. Doorduijn et al., Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial, Clin. Infect. Dis, vol.46, pp.1401-1408, 2008.

C. Roder-stolinski, G. Fischader, G. J. Oostingh, R. Feltens, F. Kohse et al., Styrene induces an inflammatory response in human lung epithelial cells via oxidative stress and NF-kappaB activation, Toxicol. Appl. Pharmacol, vol.231, pp.241-247, 2008.

E. J. Ruijgrok, A. G. Vulto, and E. W. Van-etten, Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats, J. Antimicrob. Chemother, vol.48, pp.89-95, 2001.

L. Slobbe, E. Boersma, and B. J. Rijnders, Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial, Pulm. Pharmacol. Ther, vol.21, pp.855-859, 2008.

E. Snelders, H. A. Van-der-lee, J. Kuijpers, A. J. Rijs, J. Varga et al., Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism, PLoS Med, vol.5, p.219, 2008.

T. Takazono, K. Izumikawa, T. Mihara, K. Kosai, T. Saijo et al., Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis, Antimicrob. Agents Chemother, vol.53, pp.3508-3510, 2009.

A. J. Ullmann, J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston et al., Posaconazole or fluconazole for prophylaxis in severe graft-versushost disease, N. Engl. J. Med, vol.356, pp.335-347, 2007.

P. E. Verweij, M. Ananda-rajah, D. Andes, M. C. Arendrup, R. J. Bruggemann et al., International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus, Drug Resist. Updat. 21, vol.22, pp.30-40, 2015.

L. Vistejnova, J. Dvorakova, M. Hasova, T. Muthny, V. Velebny et al., The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques, Neuro Endocrinol. Lett, vol.30, pp.121-127, 2009.

F. Witzel, R. Fritsche-guenther, N. Lehmann, A. Sieber, and N. Bluthgen, Analysis of impedance-based cellular growth assays, Bioinformatics, 2015.

J. Z. Xing, L. Zhu, J. A. Jackson, S. Gabos, X. J. Sun et al., Dynamic monitoring of cytotoxicity on microelectronic sensors, Chem. Res. Toxicol, vol.18, pp.154-161, 2005.